Martha Goldberg Aronson net worth and biography

Martha Aronson Biography and Net Worth

Chair of the Board of CONMED

Ms. Goldberg Aronson has served as Chair of the Board since October 2024, previously serving as Lead Independent Director of the Company from May 2020 to October 2024. She has had responsibility for managing global health care businesses ranging in size from $500 million to $1.0 billion. Ms. Goldberg Aronson was the Executive Vice President and President of Global Healthcare for Ecolab, Inc. (NYSE: ECL) from 2012 through 2015, having previously served as the Senior Vice President and President – North America for Hill-Rom Holdings, Inc. (NYSE:HRC) from 2010 to 2012. Prior to that, she was the Senior Vice President and Chief Talent Officer for Medtronic, Inc. (NYSE: MDT), having held various prior general management positions within Medtronic, both in the U.S. and internationally. Ms. Goldberg Aronson holds a Bachelor of Arts Degree in Economics from Wellesley College, and a Masters in Business Administration from Harvard Business School.

Ms. Goldberg Aronson also served on the board of directors of Methode Electronics, Inc. (NYSE: MEI) through September 2019, Clinical Innovations, LLC through December 2019, and Cardiovascular Systems, Inc. (NASDAQ: CSII) through 2023. Ms. Goldberg Aronson also served as a director of Beta Bionics from February 2020 through October 2022, having served as interim Chief Executive Officer from February 2022 through August 2022. The Board of Directors has determined that Ms. Goldberg Aronson is independent within the meaning of the rules of the New York Stock Exchange.

Ms. Goldberg Aronson’s qualifications for election to CONMED’s Board include her extensive experience in the global healthcare markets, including leadership roles within medical device companies, and her experience in marketing and talent development. The Board strongly believes that the Board and Company benefits from the perspectives that Ms. Goldberg Aronson brings to the Board and the Company from her business experience. She has the ability and willingness to serve on the Board, and the correct fit to work in a collegial manner with the other directors.

What is Martha Goldberg Aronson's net worth?: The estimated net worth of Martha Goldberg Aronson is at least $99,500.00 as of May 6th, 2024. Ms. Aronson owns 2,000 shares of CONMED stock worth more than $99,500 as of April 24th. This net worth approximation does not reflect any other investments that Ms. Aronson may own. Learn More about Martha Goldberg Aronson's net worth.
How do I contact Martha Goldberg Aronson?: The corporate mailing address for Ms. Aronson and other CONMED executives is 525 FRENCH ROAD, UTICA NY, 13502. CONMED can also be reached via phone at (727) 392-6464. Learn More on Martha Goldberg Aronson's contact information.
Has Martha Goldberg Aronson been buying or selling shares of CONMED?: Martha Goldberg Aronson has not been actively trading shares of CONMED during the last ninety days. Most recently, on Monday, May 6th, Martha Goldberg Aronson bought 2,000 shares of CONMED stock. The stock was acquired at an average cost of $70.98 per share, with a total value of $141,960.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company's stock, valued at $141,960. Learn More on Martha Goldberg Aronson's trading history.
Who are CONMED's active insiders?: CONMED's insider roster includes Martha Aronson (Chair of the Board), Pat Beyer (Insider), Brian Concannon (Director), Todd Garner (CFO), Richard Glaze (Chief Information Officer), Curt Hartman (Chairman of the Board, CEO & President), Daniel Jonas (Insider), John Kennedy (EVP), Stanley Peters, III (VP), Barbara Schwarzentraub (Director), Peter Shagory (EVP), and Mark Tryniski (Director). Learn More on CONMED's active insiders.
Are insiders buying or selling shares of CONMED?: In the last twelve months, CONMED insiders bought shares 3 times. They purchased a total of 6,442 shares worth more than $446,732.92. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 4,257 shares worth more than $304,074.95. The most recent insider tranaction occured on February, 11th when insider Richard Glaze sold 257 shares worth more than $16,794.95. Insiders at CONMED own 6.8% of the company. Learn More about insider trades at CONMED.
Information on this page was last updated on 2/11/2025.

Martha Goldberg Aronson Insider Trading History at CONMED

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/6/2024	Buy	2,000	$70.98	$141,960.00	2,000

Martha Goldberg Aronson Buying and Selling Activity at CONMED

CONMED Company Overview

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Today's Range

Now: $49.75

$48.63

$51.11

50 Day Range

MA: $57.48

$47.71

$63.09

2 Week Range

Now: $49.75

$46.00

$78.58

Volume

608,842 shs

Average Volume

461,822 shs

Market Capitalization

$1.54 billion

P/E Ratio

11.73

Dividend Yield

1.67%

Beta

1.28